| Autor: |
Selig DJ; Walter Reed Army Institute of Research, Experimental Therapeutics, Silver Spring, MD 20910, USA., Akers KS; United States Army Institute of Surgical Research, San Antonio, TX 78234, USA., Chung KK; Department of Medicine, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., Kress AT; Walter Reed Army Institute of Research, Experimental Therapeutics, Silver Spring, MD 20910, USA., Livezey JR; Department of Medicine, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., Por ED; Walter Reed Army Institute of Research, Experimental Therapeutics, Silver Spring, MD 20910, USA., Pruskowski KA; United States Army Institute of Surgical Research, San Antonio, TX 78234, USA.; Department of Medicine, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., DeLuca JP; Walter Reed Army Institute of Research, Experimental Therapeutics, Silver Spring, MD 20910, USA. |
| Abstrakt: |
Critical illness caused by burn and sepsis is associated with pathophysiologic changes that may result in the alteration of pharmacokinetics (PK) of antibiotics. However, it is unclear if one mechanism of critical illness alters PK more significantly than another. We developed a population PK model for piperacillin and tazobactam (pip-tazo) using data from 19 critically ill patients (14 non-burn trauma and 5 burn) treated in the Military Health System. A two-compartment model best described pip-tazo data. There were no significant differences found in the volume of distribution or clearance of pip-tazo in burn and non-burn patients. Although exploratory in nature, our data suggest that after accounting for creatinine clearance (CrCl), doses would not need to be increased for burn patients compared to trauma patients on consideration of PK alone. However, there is a high reported incidence of augmented renal clearance (ARC) in burn patients and pharmacodynamic (PD) considerations may lead clinicians to choose higher doses. For critically ill patients with normal kidney function, continuous infusions of 13.5-18 g pip-tazo per day are preferable. If ARC is suspected or the most stringent PD targets are desired, then continuous infusions of 31.5 g pip-tazo or higher may be required. This approach may be reasonable provided that therapeutic drug monitoring is enacted to ensure pip-tazo levels are not supra-therapeutic. |
